A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

PHASE3CompletedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

September 21, 2017

Study Completion Date

September 21, 2017

Conditions
Hereditary Angioedema Types I and II
Interventions
BIOLOGICAL

C1-esterase inhibitor

Trial Locations (32)

1125

Study Site, Budapest

2560

Study Site, Campbelltown

10117

Study Site, Berlin

17033

Study Site, Hershey

20157

Study Site, Milan

20815

Study Site, Chevy Chase

23298

Study Site, Richmond

28007

Study Site, Madrid

28046

Study Site, Madrid

30460

Study Site, Pilsen

35209

Study Site, Birmingham

45231

Study Site, Cincinnati

46026

Study Site, Valencia

52621

Study Site, Tel Litwinsky

55131

Study Site, Mainz

60596

Study Site, Frankfurt

64239

Study Site, Tel Aviv

64546

Study Site, Mörfelden-Walldorf

74136

Study Site, Tulsa

75231

Study Site, Dallas

85251

Study Site, Scottsdale

92037

Study Site, La Jolla

92868

Study Site, Orange

94598

Study Site, Walnut Creek

95123

Study Site, Catania

97223

Study Site, Portland

400139

Study Site, Cluj-Napoca

L8N 3Z5

Study Site, Hamilton

K1Y 4G2

Study Site, Ottawa

M4V 1R2

Study Site, Toronto

G1V 4M6

Study Site, Québec

E1 2ES

Study Site, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

CSL Behring

INDUSTRY